An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu

Completed

Conditions studied: Breast Cancer

In brief

The purpose of this study is to observe clinical outcomes of metastatic breast cancer patients whose tumors overexpress the Her2neu protein and are being treated with trastuzumab (Herceptin)either alone or combination with chemotherapy or hormonal therapy.

Key facts

Study ID

NCT00153218

Run by

Cancer Research Network

People needed

94

Starts

2004-06-01

Last updated by the study team

2012-02-14

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• patients must have metastatic breast cancer
• tumor must have been determined to be Her-2 positive 3+ by immunohistochemistry or gene-amplified by fluorescence-in-situ hybridization (FISH)
• must have received trastuzumab alone or in combination with chemotherapy or hormonal therapy
• must not have received trastuzumab in the adjuvant or neoadjuvant setting
• must have started trastuzumab treatment for metastatic disease any time between January 1996 to June 2003

You may not qualify if…

• patients who received trastuzumab prior to 1996

Where it is running

• Cancer Research Network, Inc. — Plantation, Florida, United States
• University of Pittsburgh Cancer Institute Magee-Womans Hospital — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.